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Plasma FGF-23 concentrations and its relationship with calcium-phosphate homeostasis were evaluated in 48 perimenopausal
obesewomenandin29nonobesecontrols.Serumparathyroidhormone,25-hydroxyvitaminD3,CTX1,osteocalcin,totalcalcium,
phosphorus, creatinine, and plasma intact FGF-23 concentrations were assessed. DXA of lumbar spine and femoral neck was
performedtodeterminebonemineraldensity(BMD).PlasmaiFGF-23concentrationwassigniﬁcantlyhigherinobesepatients(by
42%) and correlated with age and BMD of proximal femur (R =− 0.346; R = 0.285, resp.) but not with markers of bone turnover.
However, serum phosphorus level in obese subjects was signiﬁcantly lower. iFGF-23 concentration correlated signiﬁcantly with
body mass index (R = 0.292) and fat content (R = 0.259) in all study subjects. Moreover, a signiﬁcant correlation between iFGF-
23 and iPTH (R = 0.254) was found. No correlation between serum phosphorus or eGFR and plasma iFGF-23 and between eGFR
and serum phosphorus was found. Elevated serum iFGF-23 concentration may partially explain lower phosphorus levels in the
obese and seems not to reﬂect bone turnover.
1.Introduction
Epidemiological studies have suggested a protective eﬀect of
o b e s i t yo np o s t m e n o p a u s a lb o n el o s s[ 1]. In general, obesity
inwomenisassociatedwithlowerriskofosteoporosis,which
may be due to the beneﬁcial eﬀect of hyperestrogenemia
[2]. The obese are characterized by calciotropic hormones
disturbances, including lower 25-hydroxyvitamin-D3 (25-
OH-D3) and higher parathyroid hormone (PTH) serum
concentrations [3, 4], which increases along with the degree
of obesity [5, 6]. Lower 25-OH-D3 levels in obese may be
explained by decreased exposure to sunlight (limited mobil-
i t yo fs o m eo b e s e )[ 7], inhibited vitamin D hydroxylation in
the liver [8], and probably excessive storage of vitamin D in
adipose tissue [6].
The regulation of bone metabolism is complex including
hormones and a long list of cytokines and growth factors.
Recently, a new hormone involved in calcium-phosphate
homeostasis was found—ﬁbroblast growth factor-23 (FGF-
23).FGF-23isa251-aminoacidresiduesproteinthatbelongs
to FGF family [9]. Fibroblast growth factors regulate the
development of subcutaneous white adipose tissue (scWAT);
however only ﬁve of them (FGF-1, 2, 7, 9 and 18) and
not FGF-23 were identiﬁed in scWAT [10]. Osteocytes and
osteoblast turned out to be the major physiological sources
of FGF-23 [11–13]. FGF-23 regulates serum phosphate and
1,25(OH)2D3 levels by acting on the kidney and intestines.
FGF-23 reduces serum phosphorus level by suppressing
proximal tubular phosphorus reabsorption (similarly to
PTH) and, in indirect way, intestinal phosphorus absorp-
tion [14]. FGF-23 also suppresses the expression of 1α-
hydroxylase and enhances the expression of 24α-hydroxylase
in the kidney, causing the reduction of serum 1,25(OH)2D3
level [14].2 International Journal of Endocrinology
Table 1: Characteristics of obese women and controls.
Obese N = 48 Controls N = 29
Age (yrs) 55.4 (53.6–57.1) 50.4 (46.0–54.7) P = 0.22
Body mass (kg) 94.5 (90.6–98.3) 62.4 (59.2–65.6) P<0.001
BMI (kg/m2) 36.5 (35.1–37.9) 23.5 (22.4–24.6) P<0.001
Waist circumference (cm) 106.7 (103.3–110.1) 82.3 (78.3–86.4) P<0.001
Fat tissue content (%) 49.6 (47.8–51.3) 35.2 (32.3–38.2) P<0.001
BMD L2–L4 (g/cm2) 1.196 (1.133–1.259) 1.035 (0.930–1.140) P = 0.023
BMD proximal femur (g/cm2) 1.026 (0.976–1.076) 0.858 (0.808–0.909) P<0.001
BMC L2–L4 (g/cm) 65.0 (60.7–69.3) 56.4 (51.1–61.7) P = 0.036
BMC proximal femur (g/cm) 4.87 (4.58–5.16) 4.23 (3.81–4.64) P = 0.030
Creatinine (mg/dL) 0.64 (0.61–0.67) 0.66 (0.61–0.71) P = 0.77
eGFR (mL/min) 97.4 (94.4–100.3) 99.5 (92.7–106.3) P = 0.46
Total calcium (mmol/L) 2.22 (2.18–2.25) 2.19 (2.13–2.25) P = 0.52
Phosphorus (mmol/L) 1.04 (1.00–1.08) 1.15 (1.09–1.21) P = 0.003
25(OH)D3 (ng/mL) 30.2 (26.2–34.2) 43.5 (34.8–52.1) P = 0.016
Osteocalcin (ng/mL) 19.1 (17.4–20.9) 24.0 (20.4–27.6) P = 0.026
iPTH (pg/mL) 47.3 (42.2–52.3) 35.4 (30.4–40.4) P = 0.002
CTX1 (ng/mL) 0.24 (0.21–0.27) 0.28 (0.21–0.35) P = 0.73
iFGF-23 (ng/mL) 9.14 (7.12–11.15) 6.44 (5.70–7.18) P = 0.005
PTH: parathormone; CTX1: C-terminal telopeptide of collagen type I; BMI: body mass, BMD: bone mineral density, BMC: bone mineral content, iFGF-23:
intact ﬁbroblast growth factor 23, eGFR: estimated glomerular ﬁltration rate.
An association of plasma FGF-23 concentration with
metabolic syndrome has already been proved [15]; however
there are no data evaluating its association with bone
metabolism in the obese. The aim of this study was to evalu-
ate plasma FGF-23 concentrations and its relationship with
calcium-phosphate homeostasis in obese perimenopausal
women.
2.MaterialsandMethods
Forty-eight obese perimenopausal women were enrolled
into this study (Table 1). Each woman was diagnosed with
simple obesity without concomitant diseases. None of them
underwent ovariectomy. All subjects were informed about
the nature of the study and signed their informed consent
forms. The exclusion criteria included current or recent
(preceding 3 months) infections, pharmacotherapy aﬀecting
bone metabolism, cigarette smoking, and drinking of more
than 2 alcohol beverages a week. The control group consisted
of 29 nonobese healthy women (Table 1).
Body mass index (BMI) was calculated based on height
and weight measurements. Blood sample was obtained from
each subject between 8.00 and 9.00am, after an overnight
fast. Serum creatinine, total calcium, and phosphorus con-
centrations were measured using the commercially available
test kits (Roche, Switzerland). Glomerular ﬁltration rate
(eGFR) was estimated using the CKD-EPI formula [16].
Plasma and serum samples for intact ﬁbroblast growth
factor23(iFGF-23),intactparathyroidhormone(iPTH),25-
OH-D3,C T X 1, and osteocalcin estimations were stored at
−80◦C until the time of the assay.
2.1. Laboratory Measurements. Intact FGF-23 was measured
by ELISA (Immutopics, San Clemente, USA). The Electro-
chemiluminiscent ImmunoAssay (Elecsys, Roche Diagnos-
tics GmbH, Germany) was used for iPTH, osteocalcin, and
C-terminal telopeptide of type I collagen (CTX1) assays.
25-(OH)-D3 was measured using RIA method (Bio Source-
EUROPE S.A, Nivelles, Belgium). The concentrations of
total calcium and inorganic phosphorus were assessed using
spectrophotometer (Point Scientiﬁc Inc. MI, USA).
Body composition was analyzed using bioimpedance
method (Bodystat 1500, Bodystat Ltd., Great Britain). Dual
energy X-ray absorptiometry (DXA method) of lumbar
spine and femoral neck for BMD and BMC determinations
was performed using Lunar Prodigy Advance apparatus.
2.2. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n s±
95% conﬁdence intervals. Statistical analysis was performed
using the STATISTICA 8.0 PL software. The results were
analyzed using the Kolmogorov-Smirnoﬀ test. As iFGF-23
values show marked squvenes, logarithmic transformation
was performed for calculation of univariate correlations
and multiple regression analyses. Mann-Whitney U test
w a su s e dt oc o m p a r eo b e s et oc o n t r o lg r o u p .C o r r e l a t i o n
coeﬃcients were calculated according to Spearman. Separate
multiple regression analyses were performed to explain
variability of iFGF-23 concentrations, BMD of proximal
femur, and lumbar spine. P values <0.05 were considered to
be statistically signiﬁcant.
3. Results
Obese subjects were characterized by higher BMC and BMD
both in the lumbar spine and femoral neck. There wereInternational Journal of Endocrinology 3
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Figure 1: Correlation between BMI and iFGF-23 serum level in
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Figure 2: The lack of correlation between serum phosphorus and
iFGF-23 concentrations in obese women.
higher serum levels of iPTH and iFGF-23 (by 42%), but
lower of 25-OH-vitamin D3, phosphorus, and osteocalcin in
obese women than in controls (Table 1).
In the combined group of obese and nonobese women
iFGF-23 concentration correlated signiﬁcantly with BMI
(R = 0.292; P = 0.01) (Figure 1), body mass (R = 0.241;
P = 0.035), and fat content (R = 0.259; P = 0.024).
The relationship with waist circumference did not reach the
level of statistical signiﬁcance (R = 0.224; P = 0.073).
There was a correlation between iFGF-23 concentration
and proximal femur BMD (R = 0.321; P = 0.010)
but not lumbar spine BMD (R = 0.223; P = 0.099).
Moreover, a signiﬁcant correlation between iFGF-23 and
iPTH (R = 0.254; P = 0.026) was found. No correlation
was demonstrated between serum phosphorus or eGFR and
plasma iFGF-23 and between eGFR and serum phosphorus
(Figure 2).
In the group of obese women iFGF-23 concentration
correlated signiﬁcantly only with age (R =− 0.346; P =
0.016) and proximal femur BMD (R = 0.285; P = 0.05).
There was also a correlation with eGFR of borderline
signiﬁcance(R = 0.266;P = 0.07).Nosigniﬁcantcorrelation
was found between iFGF-23 plasma concentration and other
study parameters in controls.
Multiple regression analysis did not reveal any inde-
pendent contribution of iFGF-23 concentrations to both
proximal femur and lumbar spine BMD. The variability of
proximal femur BMD was in 36.6% explained by age (β =
−0.391; P<0.001) and BMI (β = 0.329; P = 0.006).
Similarly the variability of lumbar spine BMD was in 17.9%
explained by age β =− 0.354; P = 0.007) and serum level of
25(OH)D3 (β = 0.271; P = 0.046).
4. Discussion
To the best of our knowledge, this is the ﬁrst study that
evaluated plasma iFGF-23 concentration with reference to
bone metabolism in obesity. Our study revealed higher (by
42%) serum level of iFGF-23 in obese individuals compared
to nonobese ones.
A positive correlation between serum level of FGF-
23 and BMI, waist circumference, waist-to-hip ratio, and
triglycerides has been previously described by Mirza et al.
[15].TheauthorsconcludedthathigherserumlevelofiFGF-
23 may indicate an increased cardiovascular risk in elderly
population;howeveritsdirecttoxicityhasneverbeenshown.
The authors did not explain the potential reason of FGF-23
increase in obese individuals. Moreover, the same authors
in another study reported an association between elevated
serum iFGF-23 concentration and the overall fracture risk in
elderly men. This relation remained unaltered after adjust-
ment for BMI, BMD, glomerular ﬁltration rate, 25(OH)2D3,
PTH, and other fracture risk factors [17].
To ﬁnd out the explanation for our ﬁnding we focused
on mechanisms potentially inﬂuencing serum FGF-23 lev-
els. It has been previously shown that FGF-23 release is
regulated by vitamin D3, phosphorus, and possibly PTH.
Administration of 1,25(OH)2D3 and dietary phosphorus
load was associated with increased FGF-23 levels [18, 19].
It has been demonstrated that PTH stimulates FGF-23
expression, whereas FGF-23 suppresses PTH secretion both
in vitro and in vivo [20–22]. It was suggested that osteoblast
stimulation by PTH directly increases skeletal FGF-23 release
[19]. However the precise mechanism of this action remains
unknown.
We may suspect that higher level of PTH, previously
reportedinobesesubjects,aswellashigherdietaryphospho-
rus may both account for serum FGF-23 increase. However,
lower serum phosphorus concentrations in the obese do not
support our hypothesis on a compensatory release of FGF-
23 in the response to phosphorus accumulation. Perhaps
more important than serum phosphorus level is dietary
phorphorus intake. As it has been previously shown by
Burnett et al., sustained increase in dietary phosphorus was
associated with increasing iFGF-23 levels and declining cal-
citriol levels, while dietary phosphorus restriction reversed
these trends [23]. The magnitude of change in serum FGF-
23 level with dietary phosphorus depletion was smaller than4 International Journal of Endocrinology
with dietary phosphorus loading. It suggests that FGF-23
is a hormone that primarily promotes phosphorus wasting
[22]. In our study we did not quantify phosphorus content
in the diet or its urinary excretion; therefore we cannot
analyze the inﬂuence of phosphorus consumption on iFGF-
23 serum levels. We may suppose that elevated serum FGF-
23, observed in obese subjects, may decrease phosphorus
levels via a direct eﬀect on proximal tubular phosphate
reabsorption and/or intestinal phosphorus absorption in
addition to glomerular hyperﬁltration. The lack of correla-
tionbetweenserumphosphorusandiFGF-23concentrations
and simultaneously an almost signiﬁcant inverse correlation
between eGFR and serum phosphorus seem to support our
hypothesis.
It is well known that obesity is associated with both
functional and structural changes within the kidney [24, 25].
IncreasedGFRintheobesemayinﬂuenceserumphosphorus
and even secondarily suppress iFGF-23 secretion.
In the study group of obese women, serum iFGF-23
concentration correlated signiﬁcantly with age and proximal
femur BMD only. Surprisingly, no correlation was found
between iFGF-23 and studied markers of bone turnover, and
the more so, because the study of Wang et al. showed that
FGF-23 appeared to directly inhibit osteoblasts maturation
and matrix mineralization [26]. In our study, the osteocalcin
serum level was decreased in obese but no correlation with
FGF-23 was found. We believe that this ﬁnding might be
explained by decreased bone turnover in obese individuals,
as already described in our previous study [27]. We suspect
that the lack of signiﬁcant correlations may have resulted
from a limited number of study subjects. In line with this
explanation we have demonstrated a signiﬁcant, though
weak,correlationbetweeniPTHandiFGF-23concentrations
only in the combined group analysis. Recently Marsell et
al. have found a positive, yet very weak (R = 0.04–0.07),
correlation between serum FGF-23 and BMD in elderly
men,whichdisappearedinmultivariatecorrelationadjusting
for body weight [28]. This correlation is quite surprising;
however, it might be explained by the positive association
between FGF-23 and body weight. The authors speculated,
that osteocytes have a mechanosensory role, thus increased
mechanical load (due to a larger body weight) may stimulate
FGF-23 expression. Finally, the authors concluded that FGF-
23 is a poor marker of BMD, due to the weak strength of
correlation and its dependence on body weight.
Our study has several limitations. The main one, pre-
viously mentioned, is the lack of measurement of daily
phosphorus consumption and its urinary excretion. More-
over, metabolic and hormonal disturbances found in obese
individuals, such as higher serum PTH, eGFR, and lower
phosphorus, 25-OH-vitamin D3, and osteocalcin levels, may
inﬂuenceiFGF-23secretioninobeseindividuals. Giventhese
limitations, our study shows that obese individuals have
higher level of iFGF-23 that correlates with proximal femur
BMD. However, the mechanism by which iFGF-23 may
aﬀect bone metabolism in obese subjects remains unknown.
Further studies are necessary to elucidate the cause and role
of increased serum iFGF-23 level in the obese.
5. Conclusion
Serum levels of iFGF-23 are increased in obese peri-
menopausal women. This may partially explain lower phos-
phorus levels in obese subjects and seems not to reﬂect bone
turnover.
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